Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 11Dermatologic 6Gynecologic 2Breast 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Ovarian Neoplasms 40Breast Neoplasms 14Uterine Cervical Neoplasms 13Melanoma 13Carcinoma, Non-Small-Cell Lung 13Pancreatic Neoplasms 11Colorectal Neoplasms 10Neoplasm Metastasis 8Head and Neck Neoplasms 8Stomach Neoplasms 7Triple Negative Breast Neoplasms 6Fallopian Tube Neoplasms 6Esophageal Neoplasms 6Anus Neoplasms 6Vaginal Neoplasms 5Penile Neoplasms 5Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Carcinoma, Hepatocellular 5Vulvar Neoplasms 4Urogenital Neoplasms 4Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sarcoma, Synovial 4Oropharyngeal Neoplasms 4Neoplasms 4Multiple Myeloma 4Mesothelioma 4Carcinoma, Renal Cell 4Recurrence 3

Interventions

pembrolizumab 10Filgrastim 7Ifosfamide 4Carboplatin 4aldesleukin 3Temozolomide 3Peripheral Blood Stem Cell Transplantation 3Drug Therapy 3Docetaxel 3Cyclophosphamide 3Counseling 3fludarabine phosphate 2fludarabine 2etoposide phosphate 2cemiplimab 2belinostat 2atezolizumab 2Thiotepa 2Surveys and Questionnaires 2Radiotherapy 2Nivolumab 2Methods 2Metformin 2Early Intervention, Educational 2Doxorubicin 2Bupropion 2Blood Specimen Collection 2Amifostine 23-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 2valspodar 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Kidney Neoplasms × fludarabine × Gynecologic × Clear all
NCT02111850 2022-03-29

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
21 enrolled 22 charts
BreastDermatologicGenitourinaryGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 14 charts
BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡